Am. J. Respir. Crit. Care Med., Volume 161, Number 2, February 2000, 589-594

Natural Autoantibody to MUC1 Is a Prognostic Indicator for Non-Small Cell Lung Cancer

YUTAKA HIRASAWA, NOBUOKI KOHNO, AKIHITO YOKOYAMA, KEIICHI KONDO, KUNIO HIWADA, and MASAYUKI MIYAKE

Second Department of Internal Medicine, Ehime University School of Medicine, Onsen-gun, Ehime, Japan; and the Department of Thoracic Surgery, Kitano Hospital, Tazuke Kofukai Medical Research Institute, Osaka, Japan

A great deal of attention has been focused on the antitumor effects of anti-MUC1 humoral and cellular responses. We examined whether anti-MUC1 antibody is present in patients with lung cancer, and evaluated its prognostic value. Serum was obtained from 30 patients with nonresectable, non-small cell lung cancer (NSCLC) and 60 healthy volunteers. The presence of anti-MUC1 antibody was determined by enzyme-linked immunosorbent assay. The patients were observed for a median follow-up time of 54.0 mo. Overall survival was estimated by the Kaplan-Meier method. Multivariate analyses were performed using the Cox proportional hazards regression model. Anti-KL-6/MUC1 antibody levels of the patients were significantly lower than those of normal individuals (p < 0.001). One-year survival rate of patients with high concentrations of anti-KL-6/MUC1 antibody was significantly higher than that of patients with low levels of anti-KL-6/MUC1 antibody (90.9% versus 21.1%, p < 0.001). Anti-KL-6/MUC1 antibody status was most strongly correlated with mortality, followed by lymph node status and albumin levels, whereas sex, serum lactate dehydrogenase (LDH), and carcinoembryonic antigen (CEA) levels, and metastasis status did not correlate with mortality. These preliminary results indicate that the degree of decrease in antibody level may be associated with a patient's prognosis. Hirasawa Y, Kohno N, Yokoyama A, Kondo K, Hiwada K, Miyake M. Natural autoantibody to MUC1 is a prognostic indicator for non-small cell lung cancer.

This article has been cited by other articles:

				L. A. Vella, M. Yu, S. R. Fuhrmann, M. El-Amine, D. E. Epperson, and O. J. Finn Healthy individuals have T-cell and antibody responses to the tumor antigen cyclin B1 that when elicited in mice protect from cancer PNAS, August 18, 2009; 106(33): 14010 - 14015. [Abstract] [Full Text] [PDF]

				C J Chapman, A Murray, J E McElveen, U Sahin, U Luxemburger, O Tureci, R Wiewrodt, A C Barnes, and J F Robertson Autoantibodies in lung cancer: possibilities for early detection and subsequent cure Thorax, March 1, 2008; 63(3): 228 - 233. [Abstract] [Full Text] [PDF]

				M. D. Brundage, D. Davies, and W. J. Mackillop Prognostic Factors in Non-small Cell Lung Cancer* : A Decade of Progress Chest, September 1, 2002; 122(3): 1037 - 1057. [Abstract] [Full Text] [PDF]

				H Satoh, H Ishikawa, Y T Yamashita, M Ohtsuka, and K Sekizawa Serum sialyl Lewis X-i antigen in lung adenocarcinoma and idiopathic pulmonary fibrosis Thorax, March 1, 2002; 57(3): 263 - 266. [Abstract] [Full Text] [PDF]

				M. J. TOBIN Chronic Obstructive Pulmonary Disease, Pollution, Pulmonary Vascular Disease, Transplantation, Pleural Disease, and Lung Cancer in AJRCCM 2000 Am. J. Respir. Crit. Care Med., November 15, 2001; 164(10): 1789 - 1804. [Full Text] [PDF]

				F. Brichory, D. Beer, F. LeNaour, T. Giordano, and S. Hanash Proteomics-based Identification of Protein Gene Product 9.5 as a Tumor Antigen That Induces a Humoral Immune Response in Lung Cancer Cancer Res., November 1, 2001; 61(21): 7908 - 7912. [Abstract] [Full Text] [PDF]

				F. M. Brichory, D. E. Misek, A.-M. Yim, M. C. Krause, T. J. Giordano, D. G. Beer, and S. M. Hanash An immune response manifested by the common occurrence of annexins I and II autoantibodies and high circulating levels of IL-6 in lung cancer PNAS, August 14, 2001; 98(17): 9824 - 9829. [Abstract] [Full Text] [PDF]